Utilizing HCT116 colon carcinoma and stem‐like GBM cells, we found that inhibition of Bcl‐xL was most relevant to enhance the apoptotic effects of LXR agonists, followed by Mcl‐1 and Bcl‐2 inhibition (Figs 2F, and EV3A and B). This evidence concerns the gene BCL2 and colon carcinoma.